Inflammation relapses after steroid implant for posterior uveitis
Part of Eyes & vision clinical trials.
This study looks at how often and how severely inflammation returns (relapses) in people who have a steroid implant in the eye for non-infectious uveitis. It may help doctors understand the long-term effects of this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have non-infectious uveitis (eye inflammation not caused by an infection) that affects the back part of the eye.
- You must have had swelling in the central retina (macular edema) or continued inflammation in the back of the eye.
- You must have received a fluocinolone acetonide implant (a small steroid implant placed inside the eye) before January 2024.
- You cannot have uveitis caused by an infection.
- You must have been followed for at least 12 months after receiving the implant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses special eye scans (OCT and OCT angiography) to look at the back of the eye in people with posterior uveitis. It may help doctors better understand and monitor this condition.
This trial tests an eye implant (ILUVIEN) in children and teens ages 6 to 17 who have a type of eye inflammation called uveitis that keeps coming back. The implant releases medicine slowly over time to control inflammation and may help reduce the need for other treatments.
This trial looks at which long-acting steroid implant works better for diabetic macular swelling that did not improve enough with past treatments. It may help patients by testing a treatment option aimed at improving vision when other eye injections have not worked well.
This trial studies ways to prevent worsening vision caused by radiation damage to the retina after plaque brachytherapy for uveal melanoma. You may be randomly assigned to a medication injection, a steroid implant, or observation to see which approach best protects vision.
This study tests a new drug (GenSci048) for people with active, non-infectious uveitis in the middle or back of the eye, who are already taking oral steroids. The goal is to see if the drug can better control inflammation and reduce the need for steroids.
This study tests a combination of two medicines, mycophenolate mofetil and adalimumab, to help control eye inflammation (uveitis) and reduce the need for steroids. It is for people who still have active inflammation despite taking a steroid medication like prednisone.
Hear when a new Uveitis, Posterior trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.